Astellas Pharma Inc
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to m… Read more
Astellas Pharma Inc (ALPMF) - Net Assets
Latest net assets as of December 2025: $1.77 Trillion USD
Based on the latest financial reports, Astellas Pharma Inc (ALPMF) has net assets worth $1.77 Trillion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.61 Trillion) and total liabilities ($1.84 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.77 Trillion |
| % of Total Assets | 48.97% |
| Annual Growth Rate | 3.55% |
| 5-Year Change | 9.17% |
| 10-Year Change | 20.18% |
| Growth Volatility | 14.52 |
Astellas Pharma Inc - Net Assets Trend (2004–2025)
This chart illustrates how Astellas Pharma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Astellas Pharma Inc (2004–2025)
The table below shows the annual net assets of Astellas Pharma Inc from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $1.51 Trillion | -5.18% |
| 2024-03-31 | $1.60 Trillion | +5.84% |
| 2023-03-31 | $1.51 Trillion | +3.26% |
| 2022-03-31 | $1.46 Trillion | +5.35% |
| 2021-03-31 | $1.39 Trillion | +7.52% |
| 2020-03-31 | $1.29 Trillion | +2.45% |
| 2019-03-31 | $1.26 Trillion | -0.78% |
| 2018-03-31 | $1.27 Trillion | -0.28% |
| 2017-03-31 | $1.27 Trillion | +1.00% |
| 2016-03-31 | $1.26 Trillion | -4.45% |
| 2015-03-31 | $1.32 Trillion | +3.90% |
| 2014-03-31 | $1.27 Trillion | +19.44% |
| 2013-03-31 | $1.06 Trillion | +4.31% |
| 2012-03-31 | $1.02 Trillion | -0.29% |
| 2011-03-31 | $1.02 Trillion | -3.12% |
| 2010-03-31 | $1.05 Trillion | +2.30% |
| 2009-03-31 | $1.03 Trillion | -7.26% |
| 2008-03-31 | $1.11 Trillion | +1.08% |
| 2007-03-31 | $1.10 Trillion | -9.72% |
| 2006-03-31 | $1.22 Trillion | +63.74% |
| 2005-03-31 | $743.47 Billion | +2.15% |
| 2004-03-31 | $727.86 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Astellas Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 20.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $740.94 Billion | 48.96% |
| Common Stock | $103.00 Billion | 6.81% |
| Other Comprehensive Income | $521.58 Billion | 34.47% |
| Other Components | $147.74 Billion | 9.76% |
| Total Equity | $1.51 Trillion | 100.00% |
Astellas Pharma Inc Competitors by Market Cap
The table below lists competitors of Astellas Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
B3 S.A. - Brasil Bolsa Balcão
PINK:BOLSY
|
$16.93 Billion |
|
Tbea Co Ltd
SHG:600089
|
$16.96 Billion |
|
Global Payments Inc
NYSE:GPN
|
$17.00 Billion |
|
Yum China Holdings Inc
NYSE:YUMC
|
$17.08 Billion |
|
PTT Exploration & Production
PINK:PEXNY
|
$16.92 Billion |
|
FOX CORP. A DL-01
F:FO5
|
$16.92 Billion |
|
Fresenius SE & Co. KGaA
PINK:FSNUF
|
$16.86 Billion |
|
LENNAR CORP. B DL-10
F:LNN0
|
$16.85 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Astellas Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,595,988,000,000 to 1,513,255,000,000, a change of -82,733,000,000 (-5.2%).
- Net income of 50,747,000,000 contributed positively to equity growth.
- Dividend payments of 128,993,000,000 reduced retained earnings.
- Share repurchases of 6,960,000,000 reduced equity.
- Other comprehensive income decreased equity by 11,720,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $50.75 Billion | +3.35% |
| Dividends Paid | $128.99 Billion | -8.52% |
| Share Repurchases | $6.96 Billion | -0.46% |
| Other Comprehensive Income | $-11.72 Billion | -0.77% |
| Other Changes | $14.19 Billion | +0.94% |
| Total Change | $- | -5.18% |
Book Value vs Market Value Analysis
This analysis compares Astellas Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-03-31 | $285.93 | $9.45 | x |
| 2005-03-31 | $274.44 | $9.45 | x |
| 2006-03-31 | $424.04 | $9.45 | x |
| 2007-03-31 | $389.61 | $9.45 | x |
| 2008-03-31 | $437.75 | $9.45 | x |
| 2009-03-31 | $428.73 | $9.45 | x |
| 2010-03-31 | $450.92 | $9.45 | x |
| 2011-03-31 | $441.74 | $9.45 | x |
| 2012-03-31 | $437.70 | $9.45 | x |
| 2013-03-31 | $369.48 | $9.45 | x |
| 2014-03-31 | $563.79 | $9.45 | x |
| 2015-03-31 | $595.67 | $9.45 | x |
| 2016-03-31 | $582.61 | $9.45 | x |
| 2017-03-31 | $602.19 | $9.45 | x |
| 2018-03-31 | $623.98 | $9.45 | x |
| 2019-03-31 | $650.76 | $9.45 | x |
| 2020-03-31 | $686.62 | $9.45 | x |
| 2021-03-31 | $745.95 | $9.45 | x |
| 2022-03-31 | $789.10 | $9.45 | x |
| 2023-03-31 | $826.25 | $9.45 | x |
| 2024-03-31 | $886.83 | $9.45 | x |
| 2025-03-31 | $842.03 | $9.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Astellas Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.65%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 2.21x
- Recent ROE (3.35%) is below the historical average (10.16%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 8.28% | 11.75% | 0.57x | 1.24x | $-12.48 Billion |
| 2005 | 4.54% | 7.54% | 0.49x | 1.23x | $-40.47 Billion |
| 2006 | 8.52% | 11.79% | 0.55x | 1.30x | $-18.03 Billion |
| 2007 | 11.95% | 14.26% | 0.63x | 1.34x | $21.42 Billion |
| 2008 | 15.98% | 18.24% | 0.68x | 1.30x | $66.38 Billion |
| 2009 | 16.60% | 17.71% | 0.72x | 1.31x | $68.00 Billion |
| 2010 | 11.60% | 12.54% | 0.71x | 1.29x | $16.90 Billion |
| 2011 | 6.63% | 7.09% | 0.71x | 1.31x | $-34.46 Billion |
| 2012 | 7.68% | 8.07% | 0.69x | 1.38x | $-23.58 Billion |
| 2013 | 7.80% | 8.24% | 0.70x | 1.36x | $-23.35 Billion |
| 2014 | 7.16% | 7.97% | 0.69x | 1.30x | $-35.97 Billion |
| 2015 | 10.31% | 10.89% | 0.70x | 1.36x | $4.06 Billion |
| 2016 | 15.38% | 14.11% | 0.76x | 1.43x | $67.77 Billion |
| 2017 | 17.20% | 16.67% | 0.72x | 1.43x | $91.52 Billion |
| 2018 | 12.98% | 12.66% | 0.70x | 1.47x | $37.85 Billion |
| 2019 | 17.66% | 17.01% | 0.69x | 1.51x | $96.43 Billion |
| 2020 | 15.16% | 15.02% | 0.56x | 1.80x | $66.49 Billion |
| 2021 | 8.70% | 9.65% | 0.55x | 1.64x | $-18.02 Billion |
| 2022 | 8.50% | 9.57% | 0.56x | 1.60x | $-21.94 Billion |
| 2023 | 6.55% | 6.50% | 0.62x | 1.63x | $-52.08 Billion |
| 2024 | 1.07% | 1.06% | 0.45x | 2.24x | $-142.55 Billion |
| 2025 | 3.35% | 2.65% | 0.57x | 2.21x | $-100.58 Billion |
Industry Comparison
This section compares Astellas Pharma Inc's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $232,252,086,778
- Average return on equity (ROE) among peers: -0.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Astellas Pharma Inc (ALPMF) | $1.77 Trillion | 8.28% | 1.04x | $16.93 Billion |
| AbbVie Inc (ABBV) | $15.70 Billion | 26.61% | 0.35x | $387.90 Billion |
| Amgen Inc (AMGN) | $80.60 Million | 0.62% | 0.16x | $194.15 Billion |
| Amarin Corporation PLC (AMRN) | $24.15 Million | -158.05% | 0.75x | $303.32 Million |
| AstraZeneca PLC (AZN) | $14.91 Billion | 37.51% | 2.22x | $295.24 Billion |
| Bayer AG (BAYZF) | $20.80 Billion | 15.33% | 1.47x | $21.61 Billion |
| Biogen Inc (BIIB) | $6.43 Billion | 19.21% | 0.41x | $27.11 Billion |
| Bristol-Myers Squibb Company (BMY) | $4.75 Billion | 22.46% | 0.58x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $2.03 Trillion | 21.42% | 0.22x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $58.37 Million | 6.18% | 0.57x | $529.97 Million |